Drug General Information (ID: DDIYC23URM)
Drug Name			Reteplase		Drug Info		Ibritumomab tiuxetan		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Thrombolytics				Antineoplastics

Mechanism of Reteplase-Ibritumomab tiuxetan Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Reteplase				Ibritumomab tiuxetan
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Antiplatelet effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Reteplase and Ibritumomab tiuxetan

Recommended Action
Management		Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation. Close clinical and laboratory observation for bleeding complications is recommended during and after ibritumomab therapy.

References
1	Product Information. In-111 Zevalin (ibritumomab). IDEC Pharmaceuticals Corporation, San Diego, CA.